Tandem Diabetes Care Files 8-K on Agreements and Shareholder Votes

Ticker: TNDM · Form: 8-K · Filed: 2025-05-23T00:00:00.000Z

Sentiment: neutral

Topics: material-definitive-agreement, shareholder-vote, corporate-action

Related Tickers: TNDM

TL;DR

Tandem Diabetes Care filed an 8-K for a new deal and shareholder vote. Details to follow.

AI Summary

On May 21, 2025, Tandem Diabetes Care, Inc. filed an 8-K report detailing two key events. The company entered into a Material Definitive Agreement and submitted matters to a vote of its security holders. Specific details regarding the nature of the agreement and the matters voted upon were not fully disclosed in the provided excerpt.

Why It Matters

This filing indicates significant corporate actions by Tandem Diabetes Care, potentially impacting its business operations, financial standing, or strategic direction.

Risk Assessment

Risk Level: medium — The filing indicates material definitive agreements and shareholder votes, which can carry inherent risks depending on their nature and outcome.

Key Numbers

Key Players & Entities

FAQ

What is the nature of the Material Definitive Agreement entered into by Tandem Diabetes Care?

The provided excerpt does not specify the details of the Material Definitive Agreement.

What specific matters were submitted to a vote of Tandem Diabetes Care's security holders?

The excerpt mentions that matters were submitted to a vote, but does not detail what those matters are.

When was the earliest event reported in this 8-K filing?

The earliest event reported was on May 21, 2025.

What is Tandem Diabetes Care's principal executive office address?

The principal executive offices are located at 12400 High Bluff Drive, San Diego, California, 92130.

What is the SEC file number for Tandem Diabetes Care?

The SEC file number for Tandem Diabetes Care is 001-36189.

From the Filing

0001438133-25-000112.txt : 20250523 0001438133-25-000112.hdr.sgml : 20250523 20250523162145 ACCESSION NUMBER: 0001438133-25-000112 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 12 CONFORMED PERIOD OF REPORT: 20250521 ITEM INFORMATION: Entry into a Material Definitive Agreement ITEM INFORMATION: Submission of Matters to a Vote of Security Holders FILED AS OF DATE: 20250523 DATE AS OF CHANGE: 20250523 FILER: COMPANY DATA: COMPANY CONFORMED NAME: TANDEM DIABETES CARE INC CENTRAL INDEX KEY: 0001438133 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] ORGANIZATION NAME: 08 Industrial Applications and Services EIN: 204327508 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-36189 FILM NUMBER: 25982601 BUSINESS ADDRESS: STREET 1: 12400 HIGH BLUFF DRIVE CITY: San Diego STATE: CA ZIP: 92130 BUSINESS PHONE: 858-366-6900 MAIL ADDRESS: STREET 1: 12400 HIGH BLUFF DRIVE CITY: San Diego STATE: CA ZIP: 92130 8-K 1 tndm-20250521.htm 8-K tndm-20250521 0001438133 FALSE 0001438133 2025-05-21 2025-05-21   UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ____________________________ FORM 8-K ____________________________ CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 21, 2025 ____________________________ Tandem Diabetes Care, Inc. (Exact name of registrant as specified in its charter) ____________________________ Delaware 001-36189 20-4327508 (State or other jurisdiction of incorporation) (Commission File Number) (I.R.S. Employer  Identification No.) 12400 High Bluff Drive 92130 San Diego California (Zip Code) (Address of principal executive offices) Registrant’s telephone number, including area code: ( 858 )  366-6900 N/A (Former name or former address, if changed since last report) ____________________________ Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐     Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐     Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐     Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐     Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of Each Class Trading Symbol Name of Each Exchange on Which Registered Common Stock, par value $0.001 per share TNDM Nasdaq Global Market Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). Emerging growth company  ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐ ____________________________ Item 1.01 Entry into a Material Definitive Agreement. On May 21, 2025 (the “Effective Date”), Tandem Diabetes Care, Inc. (the “Company”), Tandem Diabetes Care Europe B.V. (with the Company, the “Company Entities”), F. Hoffmann-La Roche AG, Roche Diabetes Care GmbH, Roche Diabetes Care, Inc., Roche Diagnostics Operations Inc., Roche Diagnostics GmbH and Roche Diagnostics International AG (collectively, the “Roche Entities”) entered into a Settlement, Mutual Release and Cross-License Agre

View on Read The Filing